Loading
Vandetanib was the first drug shown to delay progression in medullary thyroid cancer, roughly doubling progression-free survival compared with placebo, and became the first approved therapy for the disease.
Phase 3 placebo-controlled trial of 331 patients with unresectable locally advanced or metastatic medullary thyroid cancer randomised 2:1 to vandetanib 300 mg daily or placebo.
Median progression-free survival was predicted at 30.5 versus 19.3 months (hazard ratio 0.46) with response 45 versus 13 percent (placebo responses reflecting slow disease and crossover); QT prolongation, diarrhoea and rash were the main toxicities.
Vandetanib is an approved option for progressive medullary thyroid cancer, used less since selpercatinib for RET-mutant disease.
Shares Medullary thyroid cancer, Journal of Clinical Oncology.
Shares Vandetanib, Medullary thyroid cancer.
Shares Vandetanib, Medullary thyroid cancer.
Shares Vandetanib, Medullary thyroid cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/